A detailed history of Oppenheimer & CO Inc transactions in Boston Scientific Corp stock. As of the latest transaction made, Oppenheimer & CO Inc holds 47,406 shares of BSX stock, worth $4.15 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
47,406
Previous 75,833 37.49%
Holding current value
$4.15 Million
Previous $5.84 Million 31.97%
% of portfolio
0.06%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$72.96 - $84.0 $2.07 Million - $2.39 Million
-28,427 Reduced 37.49%
47,406 $3.97 Million
Q2 2024

Aug 07, 2024

BUY
$67.33 - $77.71 $366,409 - $422,897
5,442 Added 7.73%
75,833 $5.84 Million
Q1 2024

May 06, 2024

SELL
$57.6 - $68.62 $862,963 - $1.03 Million
-14,982 Reduced 17.55%
70,391 $4.82 Million
Q4 2023

Feb 13, 2024

BUY
$48.64 - $57.81 $274,232 - $325,932
5,638 Added 7.07%
85,373 $4.94 Million
Q3 2023

Nov 07, 2023

BUY
$50.19 - $54.68 $2.1 Million - $2.29 Million
41,836 Added 110.39%
79,735 $4.21 Million
Q2 2023

Aug 02, 2023

SELL
$49.72 - $54.64 $1.63 Million - $1.79 Million
-32,767 Reduced 46.37%
37,899 $2.05 Million
Q1 2023

May 10, 2023

BUY
$45.09 - $50.03 $666,204 - $739,193
14,775 Added 26.44%
70,666 $3.54 Million
Q4 2022

Feb 07, 2023

BUY
$39.56 - $47.22 $161,563 - $192,846
4,084 Added 7.88%
55,891 $2.59 Million
Q3 2022

Nov 14, 2022

BUY
$36.71 - $109.66 $317,321 - $947,901
8,644 Added 20.03%
51,807 $2.01 Million
Q2 2022

Aug 08, 2022

BUY
$35.24 - $47.1 $564,509 - $754,494
16,019 Added 59.01%
43,163 $1.61 Million
Q1 2022

May 12, 2022

SELL
$40.9 - $45.1 $2.55 Million - $2.82 Million
-62,459 Reduced 69.71%
27,144 $1.2 Million
Q4 2021

Feb 02, 2022

SELL
$38.07 - $44.87 $32,778 - $38,633
-861 Reduced 0.95%
89,603 $3.81 Million
Q3 2021

Nov 12, 2021

SELL
$41.23 - $45.88 $19,089 - $21,242
-463 Reduced 0.51%
90,464 $3.93 Million
Q2 2021

Aug 03, 2021

BUY
$38.58 - $44.24 $76,851 - $88,126
1,992 Added 2.24%
90,927 $3.89 Million
Q1 2021

May 10, 2021

BUY
$35.27 - $39.67 $411,424 - $462,750
11,665 Added 15.1%
88,935 $3.44 Million
Q4 2020

Feb 11, 2021

BUY
$33.15 - $41.97 $1.71 Million - $2.16 Million
51,438 Added 199.13%
77,270 $2.78 Million
Q3 2020

Nov 13, 2020

SELL
$34.44 - $42.23 $74,838 - $91,765
-2,173 Reduced 7.76%
25,832 $987,000
Q2 2020

Aug 11, 2020

BUY
$30.19 - $39.11 $568,930 - $737,027
18,845 Added 205.73%
28,005 $982,000
Q1 2020

May 08, 2020

SELL
$25.83 - $45.71 $167,378 - $296,200
-6,480 Reduced 41.43%
9,160 $299,000
Q4 2019

Feb 07, 2020

SELL
$37.87 - $45.37 $304,474 - $364,774
-8,040 Reduced 33.95%
15,640 $707,000
Q2 2019

Aug 09, 2019

SELL
$34.91 - $42.98 $48,873 - $60,171
-1,400 Reduced 5.58%
23,680 $1.02 Million
Q1 2019

Apr 24, 2019

SELL
$32.91 - $40.75 $326,072 - $403,751
-9,908 Reduced 28.32%
25,080 $963,000
Q4 2018

Jan 29, 2019

SELL
$31.73 - $39.04 $717,098 - $882,304
-22,600 Reduced 39.24%
34,988 $1.24 Million
Q3 2018

Oct 26, 2018

BUY
$32.83 - $38.63 $384,767 - $452,743
11,720 Added 25.55%
57,588 $2.22 Million
Q2 2018

Aug 10, 2018

BUY
$26.84 - $34.32 $856,196 - $1.09 Million
31,900 Added 228.38%
45,868 $1.5 Million
Q3 2017

Nov 09, 2017

BUY
$26.26 - $29.17 $366,799 - $407,446
13,968
13,968 $408,000

Others Institutions Holding BSX

About BOSTON SCIENTIFIC CORP


  • Ticker BSX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,431,609,984
  • Market Cap $125B
  • Description
  • Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various ...
More about BSX
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.